A combination of enfortumab vedotin and pembrolizumab has shown promising results in treating patients with advanced bladder cancer, nearly doubling survival rates compared to chemotherapy. Additionally, Johnson & Johnson’s TAR-200 represents a novel treatment prospect, designed to sustain the local release of chemotherapy drug gemcitabine directly into the bladder. Breakthrough nanotechnology in the form of urea-powered nanorobots has also shown great potential, achieving a 90% reduction in bladder tumor size in a mouse model. These advances indicate a promising future for more targeted, effective, and less invasive bladder cancer treatments.
Silver Fox Hackers Attacking Indian Entities with Income Tax Phishing Lures
Chinese threat actors operating under the name Silver Fox are targeting Indian organizations through sophisticated phishing campaigns that impersonate legitimate income tax documents. The attack
